StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
16
Publishing Date
2023 - 10 - 03
1
2023 - 08 - 24
1
2023 - 07 - 14
1
2023 - 05 - 26
1
2022 - 12 - 26
1
2022 - 11 - 10
1
2022 - 11 - 03
1
2022 - 09 - 16
1
2022 - 07 - 06
1
2022 - 04 - 04
1
2022 - 03 - 15
1
2022 - 02 - 15
1
2021 - 12 - 21
1
2021 - 12 - 07
1
2021 - 12 - 06
1
2021 - 09 - 22
1
Sector
Health services
1
Health technology
16
Manufacturing
1
N/a
1
Tags
Agreement
12
Alliances
22
Antiviral
12
Application
9
Approval
16
Bioscience
10
Biotech
9
Biotech-bay
48
Biotech-beach
11
Breast cancer
22
Cancer
59
Chmp
11
Clinical-trials-phase-iii
14
Collaboration
23
Conference
14
Covid
14
Covid-19
16
Disease
20
Drug
25
Earnings
17
Events
20
Fda
21
Fda-approvals
10
Financial
23
Financial results
20
Genetown
12
Global
35
Growth
10
Health
13
Hepatitis
19
Hiv
41
Impact
9
Leukemia
10
License
13
Liver
11
Market
48
Money
9
N/a
225
People
19
Pharma
12
Pharmaceutical
10
Phase 2
9
Phase 3
9
Positive
13
Potential
10
Pre-clinical
9
Preclinical
10
Report
20
Research
54
Results
51
Sciences
30
Study
11
T-cell
32
Technology
9
Therapeutics
42
Therapy
52
Treatment
50
Trial
23
Trodelvy
15
Yescarta
14
Entities
Abbott laboratories
1
Adaptimmune therapeutics plc
1
Astrazeneca plc
2
Atara biotherapeutics, inc.
1
Bristol-myers squibb company
2
Celyad oncology sa
1
Eli lilly and company
2
Gilead sciences, inc.
16
Glaxosmithkline plc
1
Humanigen, inc.
1
Icon plc
1
Inovio pharmaceuticals, inc.
1
Iovance biotherapeutics, inc.
1
Johnson & johnson
1
Novartis ag
2
Novo nordisk a/s
1
Nrx pharmaceuticals inc
1
Pfizer, inc.
1
Sanofi
1
Syneos health, inc.
1
Viatris inc.
1
Symbols
ABB
31
ABLZF
16
ABT
32
ADMP
11
APDN
15
ARVL
39
AVIR
9
AZN
8
BDX
31
BIO
8
BNTX
50
COCP
8
CODX
8
CSCO
15
CVAC
19
DD
10
DHR
12
DVAX
46
ENTA
9
FNCTF
29
GE
14
GENE
10
GILD
16
GLAXF
15
GOVX
16
GSK
25
HGEN
11
HLTH
17
HON
33
IFRX
12
IVVD
9
JNJ
227
LHDX
9
LLY
49
MDT
16
MMM
16
MRK
10
MRNA
75
MSFT
11
NRXP
21
NVAX
93
NVS
12
OCGN
10
ORCL
17
PFE
41
PHG
10
QDEL
18
QGEN
12
RDHL
17
ROK
9
SAP
17
SAPGF
9
SNY
111
SNYNF
75
SRNE
16
TAK
10
TAYD
21
TMO
40
VERU
25
VXRT
19
Exchanges
Nasdaq
16
Nyse
3
Crawled Date
2023 - 10 - 03
1
2023 - 08 - 24
1
2023 - 07 - 14
1
2023 - 05 - 26
1
2022 - 12 - 26
1
2022 - 11 - 10
1
2022 - 11 - 03
1
2022 - 09 - 16
1
2022 - 07 - 06
1
2022 - 04 - 04
1
2022 - 03 - 15
1
2022 - 02 - 15
1
2021 - 12 - 21
1
2021 - 12 - 07
1
2021 - 12 - 06
1
2021 - 09 - 22
1
Crawled Time
07:00
1
09:00
1
10:00
1
11:00
2
13:00
1
13:20
1
13:30
1
14:00
3
15:00
1
16:00
1
17:00
1
18:00
1
19:00
1
Source
www.biospace.com
9
www.globenewswire.com
2
www.prnewswire.com
5
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Covid-19
symbols :
Gild
save search
Gilead to Present Latest Innovative Virology Data on Current and Potentially Transformative Therapies Across HIV and COVID-19 at IDWeek 2023
Published:
2023-10-03
(Crawled : 13:30)
- biospace.com/
GILD
|
$67.07
0.06%
0.06%
8.3M
|
Health Technology
|
-9.54%
|
O:
-1.2%
H:
0.9%
C:
0.08%
covid-19
hiv
FDA Approves Veklury® (Remdesivir) to Treat COVID-19 in People With Mild to Severe Hepatic Impairment With no Dose Adjustment
Published:
2023-08-24
(Crawled : 18:00)
- biospace.com/
GILD
|
$67.07
0.06%
0.06%
8.3M
|
Health Technology
|
-12.99%
|
O:
0.27%
H:
1.15%
C:
-1.19%
covid-19
veklury
fda
treat
FDA Approves Veklury® (Remdesivir) for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis
Published:
2023-07-14
(Crawled : 14:00)
- biospace.com/
GILD
|
$67.07
0.06%
0.06%
8.3M
|
Health Technology
|
-12.62%
|
O:
-0.13%
H:
1.34%
C:
0.76%
covid-19
veklury
fda
renal
treatment
dialysis
CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Severe Renal Impairment, Including Those on Dialysis
Published:
2023-05-26
(Crawled : 09:00)
- biospace.com/
GILD
|
$67.07
0.06%
0.06%
8.3M
|
Health Technology
|
-13.68%
|
O:
0.45%
H:
0.79%
C:
-1.17%
covid-19
veklury
chmp
renal
positive
dialysis
HIV Clinical Trials Market Research Report by Phase, Study Design, Sponsor, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
Published:
2022-12-26
(Crawled : 13:20)
- prnewswire.com
GILD
|
$67.07
0.06%
0.06%
8.3M
|
Health Technology
|
Email alert
Add to watchlist
NVO
|
News
|
$126.16
-1.93%
-0.23%
3.1M
|
Health Technology
|
Email alert
Add to watchlist
PFE
|
News
4
|
$26.27
-0.19%
-0.15%
23M
|
Health Technology
|
Email alert
Add to watchlist
SYNH
|
$42.98
0.0%
7.4M
|
Health Services
|
Email alert
Add to watchlist
ICLR
|
News
|
$308.79
0.76%
0.76%
960K
|
Health Technology
|
Email alert
Add to watchlist
LLY
|
News
|
$732.2
-1.81%
0.18%
2.1M
|
Health Technology
|
Email alert
Add to watchlist
covid-19
trials
research
global
report
hiv
impact
study
market
Cellular Immunotherapy Market Research Report by Type, Indication, Technology Type, End Use, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
Published:
2022-11-10
(Crawled : 17:00)
- prnewswire.com
GLAXF
|
News
|
$19.54
-14.18%
2.6K
|
Health Technology
|
25.66%
|
O:
-0.06%
H:
0.0%
C:
0.0%
AZNCF
|
News
|
$140.3
-4.19%
1.5K
|
Health Technology
|
16.43%
|
O:
6.22%
H:
3.13%
C:
-0.56%
NVS
|
News
|
$98.35
1.1%
0.0%
2.2M
|
Health Technology
|
19.15%
|
O:
2.81%
H:
0.43%
C:
-0.2%
JNJ
|
News
|
$148.53
-0.69%
-0.14%
9.6M
|
Health Technology
|
-14.06%
|
O:
0.18%
H:
0.0%
C:
0.0%
GSK
|
News
|
$40.86
-0.92%
-0.15%
1.7M
|
Health Technology
|
27.21%
|
O:
2.59%
H:
0.72%
C:
0.63%
BMY
|
$48.86
-0.27%
-0.02%
16M
|
Health Technology
|
-38.59%
|
O:
1.22%
H:
0.01%
C:
-1.7%
IOVA
4
|
$11.69
-1.43%
-1.45%
2.7M
|
Health Technology
|
51.28%
|
O:
6.12%
H:
4.99%
C:
4.21%
INO
|
$10.1
-2.6%
-2.67%
250K
|
Health Technology
|
375.69%
|
O:
5.5%
H:
4.35%
C:
3.48%
GILD
|
$67.07
0.06%
0.06%
8.3M
|
Health Technology
|
-18.57%
|
O:
1.43%
H:
0.36%
C:
-1.08%
ATRA
|
$0.7101
-1.18%
-1.2%
700K
|
Health Technology
|
-81.44%
|
O:
2.58%
H:
23.12%
C:
20.85%
AZN
|
News
|
$71.175
0.46%
0.46%
6.1M
|
Health Technology
|
16.05%
|
O:
7.08%
H:
0.84%
C:
-0.43%
ADAP
|
$1.085
-4.83%
-5.07%
780K
|
Health Technology
|
-45.71%
|
O:
0.0%
H:
7.14%
C:
5.71%
covid-19
research
global
immunotherapy
report
impact
technology
market
Pediatric Health Market Research Report by Type, Therapeutics, Treatment, Treatment Type, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
Published:
2022-11-03
(Crawled : 19:00)
- prnewswire.com
SNYNF
|
News
|
$94.25
-2.18%
480
|
Health Technology
|
8.65%
|
O:
-0.02%
H:
0.43%
C:
0.43%
AZNCF
|
News
|
$140.3
-4.19%
1.5K
|
Health Technology
|
16.0%
|
O:
-1.02%
H:
2.67%
C:
0.18%
NVSEF
|
News
|
$96.0
6.88%
52K
|
Health Technology
|
45.46%
|
O:
2.28%
H:
0.0%
C:
0.0%
VTRS
|
News
A
|
$11.55
1.67%
1.65%
7.2M
|
Health Technology
|
17.48%
|
O:
0.83%
H:
1.33%
C:
-0.51%
NVS
|
News
|
$98.35
1.1%
0.0%
2.2M
|
Health Technology
|
22.99%
|
O:
1.13%
H:
0.63%
C:
0.53%
LLY
|
News
|
$732.2
-1.81%
0.18%
2.1M
|
Health Technology
|
104.34%
|
O:
0.97%
H:
0.18%
C:
-2.13%
BMY
|
$48.86
-0.27%
-0.02%
16M
|
Health Technology
|
-37.58%
|
O:
0.42%
H:
0.59%
C:
-0.04%
ABT
|
News
|
$106.89
-0.65%
-0.22%
5.1M
|
Health Technology
|
11.55%
|
O:
1.43%
H:
0.41%
C:
0.25%
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
|
10.91%
|
O:
2.05%
H:
0.0%
C:
0.0%
GILD
|
$67.07
0.06%
0.06%
8.3M
|
Health Technology
|
-15.64%
|
O:
-0.4%
H:
2.75%
C:
1.52%
AZN
|
News
|
$71.175
0.46%
0.46%
6.1M
|
Health Technology
|
18.22%
|
O:
0.72%
H:
1.29%
C:
1.04%
covid-19
treatment
research
global
report
impact
health
market
CHMP Adopts Positive Opinion to Extend Indication of Veklury® (Remdesivir) for the Treatment of Pediatric Patients with COVID-19
Published:
2022-09-16
(Crawled : 11:00)
- biospace.com/
GILD
|
$67.07
0.06%
0.06%
8.3M
|
Health Technology
|
3.12%
|
O:
0.12%
H:
1.31%
C:
0.8%
covid-19
veklury
treatment
chmp
positive
Humanigen Announces Peer-Reviewed Publication in Thorax Supporting Early Treatment of Hospitalized COVID-19 Patients with Lenzilumab Guided by C-Reactive Protein
Published:
2022-07-06
(Crawled : 13:00)
- biospace.com/
HGEN
|
$0.0361
-61.5%
120M
|
Health Technology
|
-98.01%
|
O:
0.0%
H:
27.62%
C:
14.36%
GILD
|
$67.07
0.06%
0.06%
8.3M
|
Health Technology
|
7.81%
|
O:
0.72%
H:
0.41%
C:
0.18%
covid-19
treatment
lenzilumab
publication
U.S. FDA Grants Priority Review to Genentech’s Actemra for the Treatment of COVID-19 in Hospitalized Adults
Published:
2022-04-04
(Crawled : 07:00)
- biospace.com/
GILD
|
$67.07
0.06%
0.06%
8.3M
|
Health Technology
|
12.33%
|
O:
0.01%
H:
1.97%
C:
1.67%
covid-19
treatment
fda
review
Coronavirus (COVID-19) Current Therapy Market Sees Antiviral Drugs Accounting For A Large Number Of Treatments
Published:
2022-03-15
(Crawled : 16:00)
- prnewswire.com
GILD
|
$67.07
0.06%
0.06%
8.3M
|
Health Technology
|
15.27%
|
O:
0.47%
H:
0.62%
C:
-0.18%
covid-19
viral drug
treatment
drug
covid
therapy
antiviral
NRx Pharmaceuticals Announces US National Institutes of Health Study of ZYESAMI® (aviptadil) in Critical COVID-19 is Cleared to Complete Full Enrollment
Published:
2022-02-15
(Crawled : 14:00)
- prnewswire.com
NRXP
5 d
|
$3.11
1.97%
1.93%
96K
|
Manufacturing
|
1.33%
|
O:
1.66%
H:
9.15%
C:
-0.65%
GILD
|
$67.07
0.06%
0.06%
8.3M
|
Health Technology
|
9.69%
|
O:
0.01%
H:
0.65%
C:
0.35%
covid-19
zyesami
aviptadil
health
als
covid
yes
enroll
European Commission Expands Indication for Veklury (Remdesivir) for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression
Published:
2021-12-21
(Crawled : 11:00)
- biospace.com/
GILD
|
$67.07
0.06%
0.06%
8.3M
|
Health Technology
|
-7.51%
|
O:
0.0%
H:
0.17%
C:
-0.87%
covid-19
treatment
europe
risk
oxygen
covid
disease
Actemra/RoActemra approved by the European Commission to treat patients with severe COVID-19
Published:
2021-12-07
(Crawled : 10:00)
- globenewswire.com
GILD
|
$67.07
0.06%
0.06%
8.3M
|
Health Technology
|
-3.57%
|
O:
-0.14%
H:
0.0%
C:
0.0%
europe
covid
covid-19
CHMP recommends EU approval of Actemra/RoActemra to treat patients with severe COVID-19
Published:
2021-12-06
(Crawled : 15:00)
- globenewswire.com
GILD
|
$67.07
0.06%
0.06%
8.3M
|
Health Technology
|
-3.64%
|
O:
-0.07%
H:
0.0%
C:
0.0%
approval
covid
chmp
covid-19
Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients with COVID-19
Published:
2021-09-22
(Crawled : 14:00)
- biospace.com/
GILD
|
$67.07
0.06%
0.06%
8.3M
|
Health Technology
|
-6.55%
|
O:
0.47%
H:
0.15%
C:
-0.96%
covid
risk
covid-19
Gainers vs Losers
62%
38%
Top 10 Gainers
CSSE
4
|
$0.4323
183.85%
64.77%
220M
|
Consumer Services
BOF
|
$1.99
70.09%
41.21%
110M
|
ILAG
|
$0.51
6.03%
40.62%
1.7M
|
LICN
|
$0.941
68.04%
40.49%
15M
|
AMST
|
$3.31
65.5%
39.58%
70M
|
Technology Services
MTC
|
$3.615
61.38%
38.04%
9.3M
|
Technology Services
WIMI
|
$1.15
58.53%
36.92%
19M
|
Technology Services
AIH
|
$0.45
12.5%
30.92%
320K
|
Health Services
MULN
|
News
|
$3.78
38.46%
27.78%
13M
|
Information
RILY
|
$29.86
37.48%
27.26%
12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.